CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs.…
A BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.